# China NMPA Drug Inspection - Mudanjiang Wanbing Traditional Chinese Medicine Pieces Co., Ltd. - Acanthopanax senticosus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/mudanjiang-wanbing-traditional-chinese-medicine-pieces-co-ltd/c2aec307-26fc-4f6b-847f-4df8d6cd486b/
Source feed: China

> China NMPA drug inspection for Mudanjiang Wanbing Traditional Chinese Medicine Pieces Co., Ltd. published November 26, 2019. Drug: Acanthopanax senticosus. The Gansu Provincial Drug Administration released a Drug Quality Announcement on November 26, 2019, identifying 20 batch

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: Mudanjiang Wanbing Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2019-11-26
- Drug Name: Acanthopanax senticosus
- Inspection Finding: Total ash; leachate
- Action Taken: The relevant market supervision and management departments have taken necessary control measures such as sealing and seizing, and have filed or are in the process of filing cases against the units involved in the products in accordance with relevant laws and regulations. The results of the handling will be made public within three months.
- Summary: The Gansu Provincial Drug Administration released a Drug Quality Announcement on November 26, 2019, identifying 20 batches of substandard drugs produced by 19 enterprises, with Gansu Guanlan Traditional Chinese Medicine Pieces Co., Ltd. being a prominently cited manufacturer. The inspections were primarily conducted against the Chinese Pharmacopoeia 2015 Edition, Part I, and its supplements. Key violations across various traditional Chinese medicinal ingredients included non-compliance with specifications related to Total Ash, Extractives, Properties, Content Determination, Microscopic Identification, Thin-Layer Chromatography, and the presence of impurities such as insect infestation.

Regulatory actions have been swiftly implemented by market supervision departments, including the sealing and seizing of non-compliant products. Investigations against the responsible entities have commenced, with commitments to publicize the findings within three months. Furthermore, municipal and prefectural supervision bureaus are instructed to enhance oversight, ensuring that these companies conduct thorough root cause analyses, develop, and execute rectification measures to effectively mitigate potential risks to drug quality and public safety.

Company: https://www.globalkeysolutions.net/companies/mudanjiang-wanbing-traditional-chinese-medicine-pieces-co-ltd/7bae61e3-2240-44e9-aa8b-c31d07f38925/